Regenxbio’s Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Regenxbio’s gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases. Latest Ratings for RGNX Date Firm Action From To Mar 2022 SVB Leerink Maintains Market Perform Feb 2022 SVB Leerink Maintains Market Perform Jan 2022 SVB Leerink Maintains Market Perform View More…

Read More